Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD

• Status: Withdrawn
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To the best of our knowledge, there has been no randomized controlled trial to compare double dose PPI therapy with standard one dose PPI therapy for NERD patients. Thus, we hypothesize that a double dose PPI would accelerate and sustain the control of symptom in NERD patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Inje University
• Treatments: Rabeprazole

Criteria

Inclusion Criteria:

• heartburn and/or reflux at least twice weekly in the absence of visible esophageal mucosal breaks at endoscopy

Exclusion Criteria:

• pregnancy

• lactation

• Hx of gastric surgery

• Hx of gastric cancer or peptic ulcer

• major medical problems (including CHF, renal failure, COPD, asthma, liver cirrhosis)

• severe systemic illness

• Hx of malignancy, allergy Hx to rabeprazole

• patients who had taken antibiotics

• antisecretory agents including H2-blocker

• PPI within 4 weeks before endoscopy

• current usage of steroids, NSAIDs, aspirin, anticoagulant medication